He was a board member and V.P. As of 2019, seven of the top ten drugs were biologics and there are currently more than 200 biotherapeutics in use, generating more than $100 billion in annual revenue for drug companies … He is a director of multiple innovative biotechnology companies, including among others: Ra Pharmaceuticals (NASDAQ:RARX – Chairman), Rhythm Pharmaceuticals (NASDAQ:RYTM), Synlogic (NASDAQ:SYBX), ObsEva (NASDAQ:OBSV), and Liquidia Technologies (NASDAQ: LQDA). Mr. Moore holds a B.A. Previous to Raytheon Bo was at IBM where he co-engineered the computing chips behind Watson. John was previously a partner at 8VC where he led the fund’s investment efforts at the intersection of national security and defense. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors. Mr. Verstandig serves on the board of NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response that mimics natural biology. Her work supported the $4.3 billion acquisition of SPARK Therapeutics by Roche and the $11.9 billion acquisition of Kite Pharma by Gilead. At age 21, Mr. Verstandig founded Rally Health, a consumer-centric digital health company whose online and mobile tools empower millions of people to take control of their health and well-being and manage their health care needs. Founded in 2009 by Joe Lonsdale, who currently serves as an active Chairman of its Board of Directors and General Partner at 8VC… As part of the investment, Andreessen Horowitz General Partner, Vineeta Agarwala, MD, PhD joins BigHat’s Board of Directors. 8VC was founded in 2016 and manages $2.4 billion in committed capital. In February 2013, Mr. Moore co-founded NodePrime, a cloud automation company, where he served as Chief Operating Officer until its acquisition by Ericsson in April 2016. Edit. Jason Kelly. Lawrence Fong, M.D. He is a founder of 8VC, a technology investment firm, and a co-founder of Palantir Technologies, Addepar, and OpenGov, and was an early investor in a number of companies, including the e-commerce platform Wish. and M.B.A. from Columbia University where he was a Stone Scholar and currently lectures on topics in biotechnology, and graduated with honors from Dartmouth College with an A.B. He has received the NIH New Innovator Award, the US President Early Career Award for Scientists and Engineers, MIT Technology Review’s TR35, Navy and Army Young Investigator Prizes, and others. Dr. Wilson Wong is an Assistant Professor at Boston University. Dr. Fong obtained his BA from Columbia and MD from Stanford.He is an elected member of Alpha Omega Alpha and the American Society for Clinical Investigation. He is a seasoned business leader with experience in corporate strategy, finance, business development, commercialization and building high performing cell & gene therapy organizations. Previously, as a Partner at Founders Fund for over five years, Geoff was an early lead investor in the now-mainstream on-demand services, mobile commerce, legal cannabis, FinTech, and labor marketplace sectors; being amongst the first to lead sizable early stage venture rounds in companies including Lyft (NASDAQ: LYFT), Wish, Privateer Holdings (NASDAQ: TLRY), Nubank, and RigUp. Earlier in his career, Alex worked with Peter Thiel as a Principal at Mithril Capital Management, a growth-stage venture fund, where he helped lead investments in AppDirect, Adimab, C2FO and Helion Energy. Jake serves on the Advisor Board for 8VC, a successful venture capital firm in SF whose recent investments include Oculus, Wish, Blend and more. Bob Kerrey — Managing Director, Allen & Co; former U.S. The other new directors are Spencer Rascoff, a founder of Zillow, and Alexander Moore, an early Palantir employee who is now a partner at venture capital firm 8VC. Greater Los Angeles Area Companies (Top 10K) 9,745 Number of Organizations • $113.3B Total Funding … Leigh spent 8 years at Microsoft where he led the transformation of the National Security and Defense business units. Be a part of the world class team at Senti Bio and help engineer what’s next. Dr. Lee is a veteran biotech executive with over a decade of experience leading cell and gene therapy programs for human applications. Mr. Lonsdale co-founded and is a General Partner at Eight Partners VC, LLC (“8VC”), a venture capital firm. Prior to joining Senti, Curt was Senior Vice President and Chief Business Officer of a publicly traded genome editing company, Sangamo Therapeutics, where he led the business function and completed a number of global collaborations, including those with Shire rare disease, Biogen blood disorders, Pfizer rare disease, Pfizer neuroscience, and Gilead oncology. The Reporting Person, a member of the Issuer's board of directors, is the sole managing member of 8VC Co-Invest GP and may be deemed to have sole voting and dispositive power with respect to the shares held by 8VC Co-Invest LP. Prior to joining 8VC, John worked for Peter Thiel’s Valar Ventures in New York City where he was responsible for investing across a variety of sectors and helped shape the fund’s domestic investing strategy. in Religion and Public Policy. He earned his bachelor's degree in chemistry from North Carolina State University. Curt has experience working across many different disease areas and advanced therapeutic modalities including in vivo gene therapy, ex vivo cell therapy and genome editing. Dr. Andreeff is a Professor of Medicine at MD Anderson, Leukemia & Stem Cell Transplantation. While at 8VC, John was responsible for the firm’s investments in Anduril Industries, Cambium Bio Materials, Reveal AI, Calypso AI, Rebellion Defense, and Arcbyt. This is an important role within a company, as the board of directors doesn't directly control the company on this level; the board's involvement is focused more on higher-end goals and … Ran Geng is a venture investor at Matrix Partners China focused on biotech investments. The Board is collectively responsible for and has the power to conduct the general affairs of the company. Prior to becoming Chief of Staff of the Russian President he worked as Deputy … NEW YORK – April 20, 2017 – MakeSpace, the leading full-service storage provider that picks up, stores and brings back your belongings, announced today it has raised a $30 million Series C round led by 8VC.Existing investors Upfront Ventures, Harmony Partners, and Summit Action also … Prior to joining 8VC, Alex was a Partner at Formation 8. She led, or is involved in, many investments including Tallac Therapeutics, Nikang Therapeutics, InventisBio, Chameleon Bio, Peijia Medical (HK.9996) and Ambrx. Board of Directors. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Prior to joining 8VC, Alex was a Partner at Formation 8. He also holds two US patents. It is an exhilarating notion, and as a result, we’ve developed a much deeper and more trusting relationship with our board members.” Kimmy Scotti Partner, 8VC Joe is a co-founder of … Born. RHI Magnesita N.V. has a one-tier board structure with a Board consisting of both executive directors and non-executive directors (including employee representatives). However, the authority of the board is subject to the limitations imposed by the Memorandum of Association, Articles of Association of the company and there re… Previously he was a board member of Lumena (sold to Shire),  Ziarco (sold to Novartis), Motus Therapeutics (sold to Allergan), Plexxikon (sold to Daiichi Sankyo), MedImmune, LLC, and the Biotechnology Industry Organization (BIO). In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. Mr. Moore has served as a member of our Board of Directors since July 2020. Lee earned his J.D. He is the founder of the Institute for Genetic Disease Prevention and has written on innovation and ethics for Wired, Slate, Neo.Life and STAT News. As Co-Founder & Chief Executive Officer of Topguest (acquired), he created a loyalty software platform that counted United Airlines, Hilton Worldwide, and Virgin America as clients. Dr. Yungang Bao Director. Private Western US Companies (Top 10K) 9,897 Number of Organizations • $495.4B Total Funding Amount • 65,169 Number of Investors. Dr. Jim Collins is the Termeer Professor of Medical Engineering and Science in the Institute for Medical Engineering and Science as well as Professor of Biological Engineering at MIT. In connection with the financing, Francisco Gimenez, Ph.D., of 8VC will join the Company's board of directors. Unlike the board of directors, the CEO is a member of the company's management. Responsibilities include: 1. Alex Moore has served as a member of our Board of Directors since July 2020. He is a recipient of the AIChE Bailey Award, the Merck Cell Culture Engineering Award, and the Gaden Award, among others. His career has spanned public accounting, operational finance, and corporate finance. He is an expert at mammalian synthetic biology. John holds a B.A. Alex Kolicich is a Founding General Partner of 8VC where he leads the firm's Bio-IT investments. Cofounder and CEO. Prior to venture, he was an early engineer and product advisor at Clarium Capital, Palantir, and Google. John began his career at Allen & Company, where he worked in the firm’s capital markets and investment management divisions. He resides in the greater Washington, D.C. area. He received his PhD in Bioengineering from UC Berkeley/UCSF and B.S. Mr. Verstandig advises multiple government organizations, including serving as a senior advisor to the National Security Agency on advanced analytics, technology, and Artificial Intelligence. The board of directors establishes corporate policies, makes high-level management decisions and creates policies to guide the efforts of the organization. Mr. Moore initially joined Palantir in February 2005 as one of the founding employees and served as our director of operations until March 2010. Earlier in his career, Alex worked with Peter Thiel as a Principal at Mithril Capital Management, a growth-stage venture fund, where he helped lead investments in AppDirect, Adimab, C2FO and Helion Energy. Outsmarting complex diseases with more intelligent medicines. Mr. Verstandig is also the Co-founder of Spycraft Entertainment, a content and entertainment production company focused on the most important intelligence and military operations that have shaped the world around us. He is a co-founder of Synlogic (NASDAQ: SYBX), Tango Therapeutics, Sample6, Eligo, BiomX, and Engine Biosciences. Using this approach, Jim has pioneered innovative ways to detect and treat infections, and to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance. While at Raytheon, Dr. Marr won the President's award for innovation, filed over 70 US and international patents, and was a technical lead on the Next Generation Jammer program. In addition to co-founding Senti Biosciences, he is a co-founder of EnBiotix, Synlogic (NASDAQ: SYBX) and Sherlock Biosciences. © 2020 Epirus Inc. Epirus® is a registered trademark of Epirus, Inc. Epirus named to Built in LA’s prestigious 2021 “best places to work” list, Epirus, Inc. Raises $70M in Series B Funding, Advancing Directed Energy For Defense and Commercial Applications. Joe Lonsdale. Prior to joining our Board of Directors, Mr. Voloshin served as Chairman of the Board of MMC Norilsk Nickel from 2008 to 2010 and as Chairman of the Board of Directors of RAO "UES of Russia" from 1999 to 2008. Mr. Verstandig is an active entrepreneur, venture capital investor, and philanthropist. Since March 2017, Mr. Verstandig has served as the Chief Digital Officer of UnitedHealth Group, one of the world’s largest diversified healthcare companies. Director of Research … Serving as CTO and then engineering lead at Epirus, through experimentation and iteration, Bo co-invented SmartPower and the solid state technologies being used today, including discovery of an exponential trend in Gallium Nitride and also some resonant properties key to Epirus' products. Prior to joining NEA, Ed most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. Mr. Moore initially joined Palantir in February 2005 as one of the founding employees and served as our director of operations until March 2010. Financial Statements - Review financial statements and earnings releases; discuss and review accounting policies an… Prior to her current role, Dr. Cooperstone held a variety of leadership positions at Pfizer in clinical development and global medical affairs, with oversight over a wide range of therapeutic areas, including small and large molecules in early through late phase development, and in-line support. Alex Kolicich is a Founding General Partner of 8VC where he leads the firm's Bio-IT investments. degree in Chemical Engineering from UC Berkeley, Wilson conducted his Ph.D. thesis work in the laboratory of Prof. James Liao at UCLA and his postdoctoral studies in the laboratory of Prof. Wendell Lim at UCSF. David Moskowitz , Ph.D., also of 8VC, becomes a board observer. Mr. Moore initially joined us in February 2005 as one of the founding employees and served as our director of operations until March 2010. Do you dare to dream what could be, thinking outside the “box”, pushing the boundaries? Ken is a senior finance executive, most recently the Corporate Vice President and Chief Financial Officer of Northrop Grumman Corporation. Alex Moore has served as a member of Epirus’s Board of Directors since July 2020. Lee is Director of Venture Investments with Leaps by Bayer, where he aims to contribute to new biotechnologies that enable patients and communities to live healthier lives. Our industry-leading partners share our vision of synthetic biology becoming an important pillar in next-generation cell and gene therapy. He received his MD/PhD from MIT and Harvard. Board of Directors. Mr. Verstandig is also a member of the National Council for the American Enterprise Institute and is a founding member and Director of the Greater Washington Partnership. Jim is widely heralded as one of the founders of the field of synthetic biology, which applies engineering principles to the biological sciences in order to program novel gene circuits that can better control cellular behavior. The predecessor firm Formation 8 was founded in 2012 and today, manages $1.1 billion in committed capital. The partners have a proven track-record as founders, engineers, and operators of successful companies including Palantir, Addepar, Affinity and OpenGov, among others. Before Microsoft, Leigh served in leadership roles at EMC, VMware, Applied Marine Technology and SAIC with a focus on national security. The state a company incorporates in will determine how many directors the board … In February 2013, Mr. Moore co-founded NodePrime, a cloud automation company, where he served as Chief Operating Officer until its acquisition by … Bo is a Graduate Fellow of the National Science Foundation and holds a Ph.D. in electrical and computer engineering from Georgia Institute of Technology. Sign up with your email address to receive news and updates. Geoff Lewis is a Founder and Managing Partner of Bedrock. degree in Human Biology from Stanford University and a Master of Business and Science (M.B.S.) of Operations for Marine Acoustics, Inc. prior to spinning out and commercializing Voxtec International product development. After completing his B.S. Prior to joining Leaps, Lee was Entrepreneur-in-Residence with RA Capital and founder of Enlight Bio, a biotech focused on genetic disease. Clay's principal focus is reforming parole and probation systems in the states so that they concentrate correctional resources on helping the 4.5 million people in community corrections regain their footing and start new lives. Her investments have led to three positive clinical proof-of-concepts. from McGill University, and completed her residency in pediatrics at the Montreal Children’s Hospital, her clinical fellowship in pediatric nephrology at Children’s Hospital of Philadelphia and a research fellowship at the University of Pennsylvania’s Renal Electrolyte division. in Chemical Engineering from California Institute of Technology and his Ph.D. in Chemical Engineering from U.C. Every entrepreneur wants to have an amazing board of directors for their start-up but like it or not, your company’s board will be created off your earliest investors. Curt Herberts joined our team in June 2018 and is responsible for leading the business operations, finance, corporate development, legal and people functions at Senti. Then Epirus is the place for you! Ahmad (Mo) Khalil is Assistant Professor of Biomedical Engineering and the Associate Director of the Biological Design Center at Boston University, and a Visiting Scholar at the Wyss Institute at Harvard University. Ramsey Homsany. CEO - Gingko Bioworks. While at Google Research, Alex worked on the launch of Google Street-Views and Google Checkout. Dr. Iglesias is a seasoned oncology medical professional, with over 30 years of global experience in executive positions within large pharma and biotechnology companies including Abraxis, Celgene, Eli Lilly, Boston Biomedical, Apobiologix, Biothera Pharmaceuticals and Bionomics. Alex Moore has served as a member of our Board of Directors since July 2020. He was an early institutional investor in many notable companies including Wish, Oculus, Oscar, Illumio, Blend, RelateIQ, Joby Aviation, Guardant Health, and Synthego, and in 2016 and 2017 was the youngest member of the Forbes 100 Midas List. He is a co-founder of Synlogic (NASDAQ: SYBX), Tango Therapeutics, Sample6, Eligo, BiomX, and Engine Biosciences. As Pfizer’s CDO, Dr. Cooperstone is responsible for advancing and managing the development portfolio of its rare disease business, including advanced technology platforms such as gene therapy. Prior to joining 8VC in 2015, he was a founding partner of Formation8 GP LLC, the precursor venture fund to 8VC, and co-founded Palantir Technologies, a global software company, in 2003. Board Profile . He has extensive experience in all aspects of oncology and immuno-oncology clinical development, from early phase and translational research to post-market studies, including pivotal trials that have enabled product approvals. We are truly excited to partner with Bhaskar Ghosh and the dynamic team at 8VC, as well as Venu Pemmaraju and Wipro on our mission to simplify the database tier for modern applications and help enterprises move to the cloud without lock in. During his 8 years at Northrop Grumman, Ken helped the company win the B-21 Raider contract and strategically positioned the company for the GBSD program. Mr. Berquist joined Marriott in 2002 after a 28-year career with Arthur Andersen LLP, … Mr. Herberts holds a B.A. Bo also holds an Epirus board seat. Joe … In addition, she is site leader for the company’s Collegeville campus. in Government from Georgetown University. Co-Founder and. Wilson is an expert in immune cell engineering as well as metabolic pathway engineering. He leads digital innovation across the enterprise, which provides healthcare coverage to nearly 50 million people through its UnitedHealthcare division as well as technology-enabled health services to improve system performance and deliver care to nearly 100 million consumers through its Optum division. From 1999 to 2003 Mr. Voloshin headed the Russian Presidential Administration. Prior to joining Founders Fund in 2012, Geoff was a founder himself. Outside of work, Curt lives in the Bay Area peninsula and enjoys spending time with his wife and two kids, running on trails around his house, and snowboarding in the Sierras. He also works on policy reforms which cut wasteful spending and … He is also an active member of the Young Entrepreneurs Council, GenNext, Napa Valley Vintners and Napa Valley Grapegrowers. JT began his civilian business career at J.P. Morgan in fixed income, followed by his roles as a Director at Proxicom, Inc., a leading e-business consulting agency where he was an account executive for companies …